This recent update provides increased access to the AngioDynamics NanoKnife IRE ablation system across the UK resulting in a better quality of life for patients being treated for prostate cancer who qualify for focal therapy.
Benefits to the patient have been proven with 93% of patients maintaining erectile function* following NanoKnife treatment and 89% rate of negative biopsies.**
As the UK distributor for NanoKnife, we are very excited by this update and keen to speak with anyone who is potentially interested in setting up an IRE service or would like to know more about NanoKnife.
* The meta-analysis of the data from the Alkemi literature summary P019208 NanoKnife Clinical Evidence Report.
** Meta-analysis comparing rates across all time periods reported.
FURTHER INFORMATION
Aquilant Ltd (an HC21 company)
E: oncology@hc21.group
www.healthcare21.eu
https://healthcare21.eu/hc21-news/an-exciting-update-from-our-partner-angiodynamics/
